Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Werewolf TherapeuticsHOWL +4.84%31 Cash-to-Debt is No Debt (1) as of Jun. 2026, which is 100% below its 10-year median of 3.51. GuruFocus rates HOWL with a GF Scoreâ„¢ of 31/100. The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, Werewolf Therapeutics ranks worse than 83.27% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Werewolf Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Werewolf Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Werewolf Therapeutics's Cash-to-Debt or its related term are showing as below:
HOWL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.58 Med: 3.51 Max: No Debt
Current: 0.58
During the past 7 years, Werewolf Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.58. And the median was 3.51.
HOWL's Cash-to-Debt is ranked worse than 83.27% of 1399
companies
in the Biotechnology industry
Industry Median: 6.49
vs HOWL: 0.58
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Werewolf Therapeutics Cash-to-Debt Related Terms
Werewolf Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Werewolf Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Werewolf Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Werewolf Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Werewolf Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Werewolf Therapeutics's Cash-to-Debt falls into.
Werewolf Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:
Werewolf Therapeutics had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Werewolf Therapeutics (HOWL) has a Cash-to-Debt of No Debt (1) as of Jun. 2026. This is 72% below median its historical median of 3.51. Over the past decade, Werewolf Therapeutics' Cash-to-Debt has ranged from 0.58 to 10,000.00. According to the industry distribution chart, Werewolf Therapeutics ranks #1165 out of 1399 companies in the Biotechnology industry, placing it in the top 83.3%.
Is Werewolf Therapeutics' Cash-to-Debt too high?
Werewolf Therapeutics' current Cash-to-Debt of No Debt (1) is 72% below median its 10-year median of 3.51. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 10,000.00. Based on the distribution chart, Werewolf Therapeutics ranks #1165 out of 1399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Werewolf Therapeutics has a GF Scoreâ„¢ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Werewolf Therapeutics' Cash-to-Debt compare to CVM and MRKR?
According to the Biotechnology industry distribution chart, Werewolf Therapeutics ranks #1165 out of 1399 companies for Cash-to-Debt. This places Werewolf Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 6.49. Historically, Werewolf Therapeutics' own Cash-to-Debt has ranged from 0.58 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.49, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Werewolf Therapeutics's current Cash-to-Debt is No Debt (1), which is 72% below median its own 10-year median of 3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Werewolf Therapeutics stock overvalued right now?
Werewolf Therapeutics (HOWL) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 72% below median its 10-year median of 3.51. Werewolf Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Werewolf Therapeutics (HOWL), the current Cash-to-Debt is No Debt (1) as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
31GF Score
Get the complete analysis for HOWL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HOWL has been successfully added to your 
